Latest news with #NMOSD
Medical News Today
a day ago
- Health
- Medical News Today
Uplizna: Dosage, side effects, uses, interactions, cost, and more
The Food and Drug Administration (FDA) approves prescription drugs such as Uplizna to treat certain conditions. Uplizna may also be used off-label for other conditions. Off-label drug use is when an FDA-approved drug is prescribed for a purpose other than what it's approved for. Uplizna for NMOSD Uplizna is FDA approved to treat NMOSD in certain adults. Specifically, it's used in adults who test positive for an antibody (a type of immune system protein) called anti-aquaporin-4 (AQP4). NMOSD is a long-term autoimmune disorder that damages nerves in your eyes and spinal cord. Autoimmune disorders occur when your immune system mistakenly attacks healthy tissue in your body. With NMOSD, your immune system mistakenly attacks nerve cells in your spinal cord and optic nerves. This stops these nerves from sending messages correctly. Symptoms of NMOSD can include: eye pain vision changes, such as dim or blurry vision pain, tingling, or numbness muscle spasms or weakness trouble walking problems with bladder or bowel control hiccups nausea and vomiting With NMOSD, you typically have periods where your symptoms flare up or worsen. These are called relapses or attacks. They may be followed by periods of remission, where your symptoms get better or go away. Uplizna helps to stop your immune system from attacking your optic nerves and spinal cord. This helps prevent the number and severity of relapses you may have. It may also lower your risk of needing hospital treatment for your symptoms. For this purpose, Uplizna may be prescribed on its own or with other drugs for NMOSD. Examples of other drugs that doctors may prescribe with Uplizna include corticosteroids, such as methylprednisolone (Medrol) and prednisone. Uplizna for IgG4-RD Uplizna is FDA approved to treat IgG4-RD in adults. Doctors may also call this condition IgG4-related sclerosing disease or IgG4-related systemic disease. IgG4-RD is a long-term autoimmune disorder that damages tissues and organs throughout your body. Autoimmune disorders occur when your immune system mistakenly attacks healthy tissue in your body. With IgG4-RD, your immune system mistakenly attacks many different tissues and organs in your body. This can cause widespread inflammation and damage to multiple organs. The organs and tissues most often affected by IgG4-RD include the pancreas, salivary glands, eyes, and tissues around the digestive organs. Other organs affected include the liver, kidneys, lungs, heart, and thyroid. Symptoms of IgG4-RD can vary, depending on what part of the body is affected. They can include: lumps, masses, or swellings dry mouth or eyes bulging eyes shortness of breath belly or back pain weight loss fatigue headaches With IgG4-RD, your symptoms may be ongoing, or they may flare up or get worse from time to time. You may also develop new symptoms if more parts of your body become affected. Flare-ups are also called relapses or attacks. Some people may also have periods of remission, where their symptoms get better or go away for a time. Uplizna helps to stop your immune system from attacking healthy tissues in your body. This helps prevent the number and severity of relapses you may have. For this purpose, Uplizna may be prescribed on its own or with other drugs for IgG4-RD. Examples of other drugs that doctors may prescribe with Uplizna include corticosteroids, such as methylprednisolone (Medrol) and prednisone. Uplizna and children Uplizna is not FDA-approved for any use in children. It's not known if the drug is safe or effective in children.
Hans India
08-05-2025
- Health
- Hans India
Rare neurological disorder treated by team of doctors
Visakhapatnam: A team of doctors at Care Hospitals successfully treated a 35-year-old woman Radha Rani, who was diagnosed with a rare neurological disorder Neuromyelitis Optica Spectrum Disorder (NMOSD) that caused severe spinal cord inflammation. She was completely bed-ridden when she was admitted to the hospital with complete loss of movement and sensation in her lower limbs. After treatment, the patient has been completely recovered, regaining mobility plus bladder control. Speaking on the occasion, MGV Aditya, senior neurologist, 'NMOSD with Longitudinally Extending Transverse Myelitis is an extremely rare condition with an estimated prevalence of 1 in 3 lakh individuals. Timely diagnosis and aggressive treatment are crucial.' The multidisciplinary team included AV Venugopal, senior consultant nephrologist and Srinivas, along with the critical care team, who worked together in the intensive care and management of the patient during her recovery journey. 'This case reinforces our commitment to delivering world-class, evidence-based treatment even in rare and complex cases. Radha Rani's full recovery is a testament to the skill, coordination, and dedication of our clinical team,' said Mayukh Chaudhuri, HCOO of the hospital.
